New research says both vaccines are very effective in counteracting the effects of B1617.2 – first identified in India – after the second dose.
The Pfizer-BioNTech and Oxford-AstraZeneca vaccines have been found to be very effective against the type of coronavirus that was first identified in India, according to a Public Health England (PHE) study.
The Pfizer vaccine was 88% effective and the AstraZeneca jab was 60% resistant to B1617.2 strains after the second dose.
Both vaccines were very effective in counteracting the “Kent” stress – B.1.1.7, a British-known COVID-19 type – with Pfizer being 93% effective while AstraZeneca jab was 66% effective at the same time.
However, it was only 33% active after three weeks after taking the first dose.
Health Secretary Matt Hancock described the results as “explosive,” while PHE said he hoped to see higher performance against hospital admissions and deaths.
“This new evidence is being undermined and confirms that our COVID-19 vaccine program is critical to protecting our loved ones,” Hancock said.
Earlier this month, the World Health Organization (WHO) are mentioned B1617.2 addresses the “global needs”.
The study, conducted between April 5 and May 16, found that both vaccines were 33% effective against B1617.2 strains after 3 weeks from baseline, compared with approximately 50% against B.1.1. 7 stress.
12,675 gene-related cases were included in the analysis, but only 1,054 were found in India. The study also included information for all ages from April 5 to meet the time since the problem began.
New data from PHE indicates that there have been at least 2,889 cases of B1617.2 cases recorded in England from February 1 this year to May 18.
Of these, 104 cases led to a visit to the emergency medical department, 31 had to be admitted to the hospital overnight and six were killed.
The most common problem in England, according to information, is version B.1.1.7, with 132,082 cases written immediately. The epidemic has killed 4.46 million people and caused 128,000 deaths in the UK since its inception last year.
Dr Mary Ramsay, chief of the vaccine at PHE, added: “This study confirms that both types of vaccines provide adequate protection against symptomatic infections from type B1617.2.
“We hope the vaccine will be of great help in preventing hospitalization and death, which is why it is important that the vaccine be protected from all available and emerging sources.”
The most vaccinated program in Europe
A separate PHE study shows that the vaccine program has prevented 13,000 deaths and an estimated 39,100 hospitalization for the elderly in England, as of May 9.
Under government opinion, removal of the remaining coronavirus inhibitors should be done from June 21st.
Recent statistics show that more than 50 million coronavirus vaccines have been delivered to Britain in the fastest-growing program in Europe to date, but it has faced a new challenge due to the spread of the first species found in India.
Most of the latest news on Saturday showed new COVID cases reported in Britain rose by 10.5% in the seven days to May 22, even though it was close to what was seen earlier this year.
Prime Minister Boris Johnson this month ordered the release of a second vaccine for more than 50 people and those at risk in hospital.
Concerns about the growing number of lawsuits in Britain over the first of its kind in India prompted Germany to state on Friday that anyone entering the country from the United Kingdom should be held within two weeks of their arrival.